Cotinga Pharmaceuticals EV/EBITDA
What is the EV/EBITDA of Cotinga Pharmaceuticals?
The EV/EBITDA of Cotinga Pharmaceuticals, Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with ev/ebitda similar to Cotinga Pharmaceuticals
- Adrabbit has EV/EBITDA of N/A
- Chipotle Mexican Grill has EV/EBITDA of N/A
- Azarga Metals has EV/EBITDA of N/A
- redT energy plc has EV/EBITDA of N/A
- Astra has EV/EBITDA of N/A
- Shield Therapeutics Plc has EV/EBITDA of N/A
- Cotinga Pharmaceuticals has EV/EBITDA of N/A
- Cubicfarm Systems Corp has EV/EBITDA of N/A
- LQwD FinTech has EV/EBITDA of N/A
- CBK has EV/EBITDA of N/A
- Rich Goldman has EV/EBITDA of N/A
- Englobal has EV/EBITDA of N/A
- Aurelius Minerals has EV/EBITDA of N/A